Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation

Thrombosis Journal

Volumn 8, Issue , 2010, Pages

  Jerath, Maya R ^a   Liu, Peng ^a   Struthers, Mary ^b   DeMartino, Julie A ^b   Peng, Roche ^b   Peterson, Laurence B ^b   Cumiskey, Anne Marie ^b   Yang, Lihu ^b   Rojas, Mauricio ^a   Patel, Dhavalkumar D ^a,c   Fong, Alan M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; MRL 677; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CLINICAL ASSESSMENT; HINDLIMB; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOLECULAR WEIGHT; MONOCYTE; MOUSE; NONHUMAN; TISSUE SECTION; VASCULITIS;

EID: 77956495514     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-8-14     Document Type: Article

References (19)

1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
2. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858-866. 10.1161/01.RES.0000146672.10582.17, 15514167.
3. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D, Spandidos DA. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007, 119:63-71. 10.1016/j.thromres.2005.12.016, 16480760.
4. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530. 10.1016/S0092-8674(00)80438-9, 9390561.
5. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003, 108:2498-2504. 10.1161/01.CIR.0000097119.57756.EF, 14581400.
6. Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002, 11:332-338. 10.1016/S1054-8807(02)00111-4, 12459434.
7. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188:1413-1419. 10.1084/jem.188.8.1413, 2213407, 9782118.
8. Liu P, Patil S, Rojas M, Fong AM, Smyth SS, Patel DD. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006, 26:2056-2062. 10.1161/01.ATV.0000234947.47788.8c, 16809547.
9. Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, Fong AM, Patterson C, Patel DD. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol 2008, 28:243-250. 10.1161/ATVBAHA.107.158675, 18079406.
10. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci USA 1997, 94:12053-12058. 10.1073/pnas.94.22.12053, 23699, 9342361.
11. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897. 10.1038/29788, 9732872.
12. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimon JJ, Charo IF, Taubman MB. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2002, 22:554-559. 10.1161/hq0402.105720, 11950690.
13. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82. 10.1016/S1074-7613(03)00174-2, 12871640.
14. Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE, Lobo PI, Okusa MD. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008, 74:1526-1537. 10.1038/ki.2008.500, 2652647, 18843253.
15. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008, 28:1950-1959. 10.1161/ATVBAHA.107.161224, 18818421.
16. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002, 90:488-494. 10.1161/hh0402.105956, 11884380.
17. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008, 117:1649-1657. 10.1161/CIRCULATIONAHA.107.745091, 18347211.
18. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008, 117:1642-1648. 10.1161/CIRCULATIONAHA.107.743872, 18165355.
19. Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation 2006, 114:807-819. 10.1161/CIRCULATIONAHA.105.602359, 16908772.